Referências
Principais artigos
Haupt R, Minkov M, Astigarraga I, et al; Euro Histio Network. Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. Pediatr Blood Cancer. 2013 Feb;60(2):175-84.Texto completo Resumo
Goyal G, Tazi A, Go RS, et al. International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults. Blood. 2022 Apr 28;139(17):2601-21.Texto completo Resumo
Rodriguez-Galindo C, Allen CE. Langerhans cell histiocytosis. Blood. 2020 Apr 16;135(16):1319-31.Texto completo Resumo
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: histiocytic neoplasms [internet publication].Texto completo
Artigos de referência
1. Emile JF, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016 Jun 2;127(22):2672-81.Texto completo Resumo
2. Haupt R, Minkov M, Astigarraga I, et al; Euro Histio Network. Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. Pediatr Blood Cancer. 2013 Feb;60(2):175-84.Texto completo Resumo
3. Allen CE, Merad M, McClain KL. Langerhans-cell histiocytosis. N Engl J Med. 2018 Aug 30;379(9):856-68.Texto completo Resumo
4. Goyal G, Tazi A, Go RS, et al. International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults. Blood. 2022 Apr 28;139(17):2601-21.Texto completo Resumo
5. Salotti J, Nanduri V, Pearce MS, et al. Incidence and clinical features of Langerhans cell histiocytosis in the UK and Ireland. Arch Dis Child. 2009 May;94(5):376-80. Resumo
6. Carstensen H, Ornvold K. The epidemiology of Langerhans cell histiocytosis in children in Denmark, 1975-89. Med Pediatr Oncol. 1993;21:387-8.
7. Karis J, Bernstrand C, Fadeel B, et al. The incidence of Langerhans cell histiocytosis in children in Stockholm County, Sweden 1992-2001. Proceedings of the XIX meeting of the Histiocyte Society. Philadelphia, PA: Histiocyte Society; 2003:21.
8. Alston RD, Tatevossian RG, McNally RJ, et al. Incidence and survival of childhood Langerhans cell histiocytosis in Northwest England from 1954 to 1998. Pediatr Blood Cancer. 2007 May;48(5):555-60. Resumo
9. Berry DH, Becton DL. Natural history of histiocytosis X. Hematol Oncol Clin North Am. 1987 Mar;1(1):23-34. Resumo
10. Stuurman KE, Lau L, Doda W, et al. Evaluation of the natural history and long term complications of patients with Langerhans cell histiocystosis of bone. Proceedings of the XIX meeting of the Histiocyte Society. Philadelphia, PA: Histiocyte Society; 2003.
11. Ribeiro KB, Degar B, Antoneli CB, et al. Ethnicity, race, and socioeconomic status influence incidence of Langerhans cell histiocytosis. Pediatr Blood Cancer. 2015 Jun;62(6):982-7. Resumo
12. Arico M, Girschikofsky M, Genereau T, et al. Langerhans cell histiocytosis in adults. Report from the International Registry of the Histiocyte Society. Eur J Cancer. 2003 Nov;39(16):2341-8. Resumo
13. Berres ML, Merad M, Allen CE. Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X? Br J Haematol. 2015 Apr;169(1):3-13.Texto completo Resumo
14. Rodriguez-Galindo C, Allen CE. Langerhans cell histiocytosis. Blood. 2020 Apr 16;135(16):1319-31.Texto completo Resumo
15. Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010 Sep 16;116(11):1919-23.Texto completo Resumo
16. Berres ML, Lim KP, Peters T, et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2014 Apr 7;211(4):669-83.Texto completo Resumo
17. Nelson DS, van Halteren A, Quispel WT, et al. MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis. Genes Chromosomes Cancer. 2015 Jun;54(6):361-8. Resumo
18. National Center for Biotechnology Information. Gene. BCL2L like 1. Gene id: 598. Dec 2022 [internet publication].Texto completo
19. National Center for Biotechnology Information. Gene. C-C motif chemokine receptor 7. Gene id: 1236. Oct 2022 [internet publication].Texto completo
20. Radzikowska E. Pulmonary Langerhans' cell histiocytosis in adults. Adv Respir Med. 2017;85(5):277-89.Texto completo Resumo
21. Senechal B, Elain G, Jeziorski E, et al. Expansion of regulatory T cells in patients with Langerhans cell histiocytosis. PLoS Med. 2007 Aug;4(8):e253.Texto completo Resumo
22. Murakami I, Wada N, Nakashima J, et al. Merkel cell polyomavirus and Langerhans cell neoplasm. Cell Commun Signal. 2018 Aug 22;16(1):49.Texto completo Resumo
23. Bernstrand C, Cederlund K, Sandstedt B, et al. Pulmonary abnormalities at long-term follow-up of patients with Langerhans cell histiocytosis. Med Pediatr Oncol. 2001 Apr;36(4):459-68. Resumo
24. Bhatia S, Nesbit ME Jr, Egeler RM, et al. Epidemiologic study of Langerhans cell histiocytosis in children. J Pediatr. 1997 May;130(5):774-84. Resumo
25. Gadner H, Grois N, Pötschger U, et al. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood. 2008 Mar 1;111(5):2556-62.Texto completo Resumo
26. Kilpatrick SE, Wenger DE, Gilchrist GS, et al. Langerhans' cell histiocytosis (Histiocytosis X) of bone. A clinicopathologic analysis of 263 pediatric and adult cases. Cancer. 1995 Dec 15;76(12):2471-84.Texto completo Resumo
27. Grois N, Potschger U, Prosch H, et al. Risk factors for diabetes insipidus in Langerhans cell histiocytosis. Pediatr Blood Cancer. 2006 Feb;46(2):228-33. Resumo
28. Lau L, Krafchik B, Trebo MM, et al. Cutaneous Langerhans cell histiocytosis in children under one year. Pediatr Blood Cancer. 2006 Jan;46(1):66-71. Resumo
29. Munn S, Chu AC. Langerhans cell histiocytosis of the skin. Hematol Oncol Clin North Am. 1998 Apr;12(2):269-86. Resumo
30. Poompuen S, Chaiyarit J, Techasatian L. Diverse cutaneous manifestation of Langerhans cell histiocytosis: a 10-year retrospective cohort study. Eur J Pediatr. 2019 May;178(5):771-6. Resumo
31. National Organization for Rare Disorders. Langerhans cell histiocytosis. 2021 [internet publication].Texto completo
32. Hashimoto K, Bale GF, Hawkins HK, et al. Congenital self-healing reticulohistiocytosis (Hashimoto-Pritzker type). Int J Dermatol. 1986 Oct;25(8):516-23. Resumo
33. Hamdan M, Qiao JC, Fikfak V. Adult-onset perianal Langerhans cell histiocytosis presenting as pruritus ani: a case report and review of the literature. J Med Case Rep. 2021 Jul 22;15(1):357.Texto completo Resumo
34. Suri HS, Yi ES, Nowakowski GS, et al. Pulmonary Langerhans cell histiocytosis. Orphanet J Rare Dis. 2012 Mar 19;7:16.Texto completo Resumo
35. Vassallo R, Ryu JH, Schroeder DR, et al. Clinical outcomes of pulmonary Langerhans'-cell histiocytosis in adults. N Engl J Med. 2002 Feb 14;346(7):484-90.Texto completo Resumo
36. Yeh EA, Greenberg J, Abla O, et al; North American Consortium for Histiocytosis. Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: current views and new vistas. Pediatr Blood Cancer. 2018 Jan;65(1):e26784.Texto completo Resumo
37. Barthez MA, Araujo E, Donadieu J. Langerhans cell histiocytosis and the central nervous system in childhood: evolution and prognostic factors. Results of a collaborative study. J Child Neurol. 2000 Mar;15(3):150-6. Resumo
38. Edelweiss M, Medeiros LJ, Suster S, et al. Lymph node involvement by Langerhans cell histiocytosis: a clinicopathologic and immunohistochemical study of 20 cases. Hum Pathol. 2007 Oct;38(10):1463-9. Resumo
39. Kakkar S, Kapila K, Verma K. Langerhans cell histiocytosis in lymph nodes. Cytomorphologic diagnosis and pitfalls. Acta Cytol. 2001 May-Jun;45(3):327-32. Resumo
40. Mogul M, Hartman G, Donaldson S, et al. Langerhans' cell histiocytosis presenting with the superior vena cava syndrome: a case report. Med Pediatr Oncol. 1993;21(6):456-9. Resumo
41. Ziogas IA, Kakos CD, Wu WK, et al. Liver transplantation for Langerhans cell histiocytosis: a US population-based analysis and systematic review of the literature. Liver Transpl. 2021 Aug;27(8):1181-90. Resumo
42. Leung AKC, Lam JM, Leong KF. Childhood Langerhans cell histiocytosis: a disease with many faces. World J Pediatr. 2019 Dec;15(6):536-45. Resumo
43. McClain K, Ramsay NK, Robison L, et al. Bone marrow involvement in histiocytosis X. Med Pediatr Oncol. 1983;11(3):167-71. Resumo
44. Willis B, Ablin A, Weinberg V, et al. Disease course and late sequelae of Langerhans' cell histiocytosis: 25-year experience at the University of California, San Francisco. J Clin Oncol. 1996 Jul;14(7):2073-82. Resumo
45. Nanduri V, Titgemeyer C, Brock P. Long term outcome of orbital involvement in Langerhans' cell histiocytosis. In: Proceedings of the XVII meeting of the Histiocyte Society. Stresa, Italy; 2001:176.
46. Lakatos K, Sterlich K, Pötschger U, et al. Langerhans cell histiocytosis of the orbit: spectrum of clinical and imaging findings. J Pediatr. 2021 Mar;230:174-81;e1. Resumo
47. McCullough WP, Pollock AN. Langerhans cell histiocytosis presenting as chronic otitis externa. Pediatr Emerg Care. 2017 Jan;33(1):67-9. Resumo
48. Guo Y, Ning F, Wang G, et al. Retrospective study of Langerhans cell histiocytosis in ear, nose and neck. Am J Otolaryngol. 2020 Mar-Apr;41(2):102369. Resumo
49. Nanduri VR, Pritchard J, Chong WK, et al. Labyrinthine involvement in Langerhans' cell histiocytosis. Int J Pediatr Otorhinolaryngol. 1998 Nov 15;46(1-2):109-15. Resumo
50. Neves-Silva R, Fernandes DT, Fonseca FP, et al. Oral manifestations of Langerhans cell histiocytosis: a case series. Spec Care Dentist. 2018 Nov;38(6):426-33. Resumo
51. Egeler RM, Schipper ME, Heymans HS. Gastrointestinal involvement in Langerhans' cell histiocytosis (Histiocytosis X): a clinical report of three cases. Eur J Pediatr. 1990 Feb;149(5):325-9. Resumo
52. Burnett A, Carney D, Mukhopadhyay S, et al. Thyroid involvement with Langerhans cell histiocytosis in a 3-year-old male. Pediatr Blood Cancer. 2008 Mar;50(3):726-7. Resumo
53. Goyal G, Young JR, Koster MJ, et al. The Mayo Clinic Histiocytosis Working Group consensus statement for the diagnosis and evaluation of adult patients with histiocytic neoplasms: Erdheim-Chester disease, Langerhans cell histiocytosis, and Rosai-Dorfman disease. Mayo Clin Proc. 2019 Oct;94(10):2054-71.Texto completo Resumo
54. Girschikofsky M, Arico M, Castillo D, et al. Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net. Orphanet J Rare Dis. 2013 May 14;8:72.Texto completo Resumo
55. Azouz EM, Saigal G, Rodriguez MM, et al. Langerhans' cell histiocytosis: pathology, imaging and treatment of skeletal involvement. Pediatr Radiol. 2005 Feb;35(2):103-15. Resumo
56. Lacronique J, Roth C, Battesti JP, et al. Chest radiological features of pulmonary histiocytosis X: a report based on 50 adult cases. Thorax. 1982 Feb;37(2):104-9.Texto completo Resumo
57. Porto L, Schöning S, Hattingen E, et al. Central nervous system imaging in childhood Langerhans cell histiocytosis - a reference center analysis. Radiol Oncol. 2015 Sep;49(3):242-9.Texto completo Resumo
58. Ribeiro MJ, Idbaih A, Thomas C, et al. 18F-FDG PET in neurodegenerative Langerhans cell histiocytosis: results and potential interest for an early diagnosis of the disease.J Neurol. 2008 Apr;255(4):575-80. Resumo
59. Kobayashi T, Koga Y, Ishimura M, et al. Fever and skin involvement at diagnosis predicting the intractable Langerhans cell histiocytosis: 40 case-series in a single center. J Pediatr Hematol Oncol. 2018 Apr;40(3):e148-53. Resumo
60. Prayer D, Grois N, Prosch H, et al. MR imaging presentation of intracranial disease associated with Langerhans cell histiocytosis. AJNR Am J Neuroradiol. 2004 May;25(5):880-91.Texto completo Resumo
61. Al-Ali H, Yabis AA, Issa E, et al. Hypercalcemia in Langerhans' cell granulomatosis with elevated 1,25 dihydroxyvitamin D (calcitriol) level. Bone. 2002 Jan;30(1):331-4. Resumo
62. Yap WM, Chuah KL, Tan PH. Langerhans cell histiocytosis involving the thyroid and parathyroid glands. Mod Pathol. 2001 Feb;14(2):111-5.Texto completo Resumo
63. Geissmann F, Lepelletier Y, Fraitag S, et al. Differentiation of Langerhans cells in Langerhans cell histiocytosis. Blood. 2001 Mar 1;97(5):1241-8. Resumo
64. Dehner LP. Juvenile xanthogranulomas in the first two decades of life: a clinicopathologic study of 174 cases with cutaneous and extracutaneous manifestations. Am J Surg Pathol. 2003 May;27(5):579-93. Resumo
65. Foucar E, Rosai J, Dorfman R. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): review of the entity. Semin Diagn Pathol. 1990 Feb;7(1):19-73. Resumo
66. Wang KH, Cheng CJ, Hu CH, et al. Coexistence of localized Langerhans cell histiocytosis and cutaneous Rosai-Dorfman disease. Br J Dermatol. 2002 Oct;147(4):770-4. Resumo
67. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: histiocytic neoplasms [internet publication].Texto completo
68. Gadner H, Minkov M, Grois N, et al. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 2013 Jun 20;121(25):5006-14.Texto completo Resumo
69. Büchler T, Cervinek L, Belohlavek O, et al. Langerhans cell histiocytosis with central nervous system involvement: follow-up by FDG-PET during treatment with cladribine. Pediatr Blood Cancer. 2005 Mar;44(3):286-8. Resumo
70. Watts J, Files B. Langerhans cell histiocytosis: central nervous system involvement treated successfully with 2-chlorodeoxyadenosine. Pediatr Hematol Oncol. 2001 Apr-May;18(3):199-204. Resumo
71. Dhall G, Finlay JL, Dunkel IJ, et al. Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2-chlorodeoxyadenosine. Pediatr Blood Cancer. 2008 Jan;50(1):72-9.Texto completo Resumo
72. Ng Wing Tin S, Martin-Duverneuil N, Idbaih A, et al. Efficacy of vinblastine in central nervous system Langerhans cell histiocytosis: a nationwide retrospective study. Orphanet J Rare Dis. 2011 Dec 12;6:83.Texto completo Resumo
73. Mammano S, Candiotto S, Balsano M. Cast and brace treatment of eosinophilic granuloma of the spine: long-term follow-up. J Pediatr Orthop. 1997 Nov-Dec;17(6):821-7. Resumo
74. Cantu MA, Lupo PJ, Bilgi M, et al. Optimal therapy for adults with Langerhans cell histiocytosis bone lesions. PLoS One. 2012;7(8):e43257.Texto completo Resumo
75. Goyal G, Abeykoon JP, Hu M, et al. Single-agent cladribine as an effective front-line therapy for adults with Langerhans cell histiocytosis. Am J Hematol. 2021 May 1;96(5):E146-50.Texto completo Resumo
76. Hazim AZ, Ruan GJ, Ravindran A, et al. Efficacy of BRAF-inhibitor therapy in BRAF V600E-mutated adult Langerhans cell histiocytosis. Oncologist. 2020 Dec;25(12):1001-4.Texto completo Resumo
77. Diamond EL, Subbiah V, Lockhart AC, et al. Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET Study. JAMA Oncol. 2018 Mar 1;4(3):384-8.Texto completo Resumo
78. Putters TF, de Visscher JG, van Veen A, et al. Intralesional infiltration of corticosteroids in the treatment of localised Langerhans' cell histiocytosis of the mandible: report of known cases and three new cases. Int J Oral Maxillofac Surg. 2005 Jul;34(5):571-5. Resumo
79. Kotecha R, Venkatramani R, Jubran RF, et al. Clinical outcomes of radiation therapy in the management of Langerhans cell histiocytosis. Am J Clin Oncol. 2014 Dec;37(6):592-6. Resumo
80. Allen CE, Ladisch S, McClain KL. How I treat Langerhans cell histiocytosis. Blood. 2015 Jul 2;126(1):26-35.Texto completo Resumo
81. Simko SJ, Garmezy B, Abhyankar H, et al. Differentiating skin-limited and multisystem Langerhans cell histiocytosis. J Pediatr. 2014 Nov;165(5):990-6.Texto completo Resumo
82. Hoeger PH, Nanduri VR, Harper JI, et al. Long term follow up of topical mustine treatment for cutaneous Langerhans cell histiocytosis. Arch Dis Child. 2000 Jun;82(6):483-7. Resumo
83. Dodd E, Hook K. Topical imiquimod for the treatment of childhood cutaneous Langerhans cell histiocytosis. Pediatr Dermatol. 2016 May;33(3):e184-5. Resumo
84. Imashuku S, Kobayashi M, Nishii Y, et al. Topical imiquimod for the treatment of relapsed cutaneous Langerhans cell histiocytosis after chemotherapy in an elderly patient. Case Rep Dermatol Med. 2018;2018:1680871.Texto completo Resumo
85. Kwon OS, Cho KH, Song KY. Primary cutaneous Langerhans cell histiocytosis treated with photochemotherapy. J Dermatol. 1997 Jan;24(1):54-6. Resumo
86. Sakai H, Ibe M, Takahashi H, et al. Satisfactory remission achieved by PUVA therapy in Langerhans cell hisiocytosis in an elderly patient. J Dermatol. 1996 Jan;23(1):42-6. Resumo
87. Steen AE, Steen KH, Bauer R, et al. Successful treatment of cutaneous Langerhans cell histiocytosis with low-dose methotrexate. Br J Dermatol. 2001 Jul;145(1):137-40. Resumo
88. McClain KL, Kozinetz CA. A phase II trial using thalidomide for Langerhans cell histiocytosis. Pediatr Blood Cancer. 2007 Jan;48(1):44-9. Resumo
89. Sander CS, Kaatz M, Elsner P. Successful treatment of cutaneous langerhans cell histiocytosis with thalidomide. Dermatology. 2004;208(2):149-52. Resumo
90. Zinn DJ, Grimes AB, Lin H, et al. Hydroxyurea: a new old therapy for Langerhans cell histiocytosis. Blood. 2016 Nov 17;128(20):2462-5.Texto completo Resumo
91. Lo WC, Chen CC, Tsai CC, et al. Isolated adult Langerhans' cell histiocytosis in cervical lymph nodes: should it be treated? J Laryngol Otol. 2009 Sep;123(9):1055-7. Resumo
92. Grobost V, Khouatra C, Lazor R, et al. Effectiveness of cladribine therapy in patients with pulmonary Langerhans cell histiocytosis. Orphanet J Rare Dis. 2014 Nov 30;9:191.Texto completo Resumo
93. Donadieu J, Rolon MA, Pion I, et al. Incidence of growth hormone deficiency in pediatric-onset Langerhans cell histiocytosis: efficacy and safety of growth hormone treatment. J Clin Endocrinol Metab. 2004 Feb;89(2):604-9.Texto completo Resumo
94. Imashuku S, Ishida S, Koike K, et al. Cerebellar ataxia in pediatric patients with Langerhans cell histiocytosis. J Pediatr Hematol Oncol. 2004 Nov;26(11):735-9. Resumo
95. Idbaih A, Donadieu J, Barthez MA, et al. Retinoic acid therapy in "degenerative-like" neuro-Langerhans cell histiocytosis: a prospective pilot study. Pediatr Blood Cancer. 2004 Jul;43(1):55-8. Resumo
96. Allen CE, Flores R, Rauch R, et al. Neurodegenerative central nervous system Langerhans cell histiocytosis and coincident hydrocephalus treated with vincristine/cytosine arabinoside. Pediatr Blood Cancer. 2010 Mar;54(3):416-23.Texto completo Resumo
97. Donadieu J, Armari-Alla C, Templier I, et al. First use of vemurafenib in children LCH with neurodegenerative LCH. Paper presented at: 30th Annual Histiocyte Society Meeting. Oct 28-30, 2014, Toronto, Canada. Pediatr Blood Cancer. 2015 May;62(suppl 1):S1-18.Texto completo
98. Donadieu J, Bernard F, van Noesel M, et al. Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study. Blood. 2015 Sep 17;126(12):1415-23.Texto completo Resumo
99. Kolenová A, Schwentner R, Jug G, et al. Targeted inhibition of the MAPK pathway: emerging salvage option for progressive life-threatening multisystem LCH. Blood Adv. 2017 Feb 14;1(6):352-6.Texto completo Resumo
100. Montella L, Merola C, Merola G, et al. Zoledronic acid in treatment of bone lesions by Langerhans cell histiocytosis. J Bone Miner Metab. 2009;27(1):110-3. Resumo
101. Donadieu J, Larabi IA, Tardieu M, et al. Vemurafenib for refractory multisystem Langerhans cell histiocytosis in children: an international observational study. J Clin Oncol. 2019 Nov 1;37(31):2857-65.Texto completo Resumo
102. Jenness DD, Spatrick P. Down regulation of the alpha-factor pheromone receptor in S. cerevisiae. Cell. 1986 Aug 1;46(3):345-53. Resumo
103. Caselli D, Arico M; EBMT Paediatric Working Party. The role of BMT in childhood histiocytoses. Bone Marrow Transplant. 2008 Jun;41(suppl 2):S8-13. Resumo
104. Veys PA, Nanduri V, Baker KS, et al. Haematopoietic stem cell transplantation for refractory Langerhans cell histiocytosis: outcome by intensity of conditioning. Br J Haematol. 2015 Jun;169(5):711-8.Texto completo Resumo
105. Ingram W, Desai SR, Gibbs JS, et al. Reduced-intensity conditioned allogeneic haematopoietic transplantation in an adult with Langerhans' cell histiocytosis and thrombocytopenia with absent radii. Bone Marrow Transplant. 2006 Apr;37(7):713-5. Resumo
106. Xicoy B, Ribera JM, Batlle M, et al. Sustained remission in an adult patient with Langerhans cell histiocytosis following T-cell depleted allogenic cell transplantation [in Spanish]. Med Clin (Barc). 2006 Nov 11;127(18):716. Resumo
107. Woo KI, Harris GJ. Eosinophilic granuloma of the orbit: understanding the paradox of aggressive destruction responsive to minimal intervention. Ophthal Plast Reconstr Surg. 2003 Nov;19(6):429-39. Resumo
108. Egeler RM, Thompson RC Jr, Voute PA, et al. Intralesional infiltration of corticosteroids in localized Langerhans' cell histiocytosis. J Pediatr Orthop. 1992 Nov-Dec;12(6):811-4. Resumo
109. Titgemeyer C, Grois N, Minkov M, et al. Pattern and course of single-system disease in Langerhans cell histiocytosis data from the DAL-HX 83- and 90-study. Med Pediatr Oncol. 2001 Aug;37(2):108-14. Resumo
110. ClinicalTrials.gov. A combination of vemurafenib, cytarabine and 2-chlorodeoxyadenosine in children with LCH and BRAF V600E mutation. NCT03585686. Apr 2020 [internet publication].Texto completo
111. Diamond EL, Durham BH, Ulaner GA, et al. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019 Mar;567(7749):521-4.Texto completo Resumo
112. Messinger YH, Bostrom BC, Olson DR, et al. Langerhans cell histiocytosis with BRAF p.N486_P490del or MAP2K1 p.K57_G61del treated by the MEK inhibitor trametinib. Pediatr Blood Cancer. 2020 Dec;67(12):e28712. Resumo
113. Papapanagiotou M, Griewank KG, Hillen U, et al. Trametinib-induced remission of an MEK1-mutated Langerhans cell histiocytosis. JCO Precision Oncol. 2017 Nov;1:1-5.Texto completo Resumo
114. ClinicalTrials.gov. Cobimetinib in refractory Langerhans cell histiocytosis (LCH), and other histiocytic disorders (NACHO-COBI). NCT04079179. Nov 2022 [internet publication].Texto completo
115. Mogulkoc N, Veral A, Bishop PW, et al. Pulmonary Langerhans' cell histiocytosis; radiologic resolution following smoking cessation. Chest. 1999 May;115(5):1452-5. Resumo
116. Gadner H, Grois N, Arico M, et al. A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. J Pediatr. 2001 May;138(5):728-34. Resumo
117. Goyal G, Shah MV, Hook CC, et al. Adult disseminated Langerhans cell histiocytosis: incidence, racial disparities and long-term outcomes. Br J Haematol. 2018 Aug;182(4):579-81.Texto completo Resumo
118. Nanduri VR, Pritchard J, Levitt G, et al. Long term morbidity and health related quality of life after multi-system Langerhans cell histiocytosis. Eur J Cancer. 2006 Oct;42(15):2563-9. Resumo
119. Boussemart L, Routier E, Mateus C, et al. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol. 2013 Jun;24(6):1691-7.Texto completo Resumo
120. Ottaviano F, Finlay JL. Diabetes insipidus and Langerhans cell histiocytosis: a case report of reversibility with 2-chlorodeoxyadenosine. J Pediatr Hematol Oncol. 2003 Jul;25(7):575-7. Resumo
121. Nanduri VR, Bareille P, Pritchard J, et al. Growth and endocrine disorders in multisystem Langerhans' cell histiocytosis. Clin Endocrinol (Oxf). 2000 Oct;53(4):509-15. Resumo
122. Preece MA. The effect of administered corticosteroids on the growth of children. Postgrad Med J. 1976 Oct;52(612):625-30.Texto completo Resumo
123. Howarth DM, Gilchrist GS, Mullan BP, et al. Langerhans cell histiocytosis: diagnosis, natural history, management, and outcome. Cancer. 1999 May 15;85(10):2278-90.Texto completo Resumo
124. Nanduri VR, Lillywhite L, Chapman C, et al. Cognitive outcome of long-term survivors of multisystem Langerhans cell histiocytosis: a single-institution, cross-sectional study. J Clin Oncol. 2003;21:2961-2967. Resumo
125. Braier J, Ciocca M, Latella A, et al. Cholestasis, sclerosing cholangitis, and liver transplantation in Langerhans cell histiocytosis. Med Pediatr Oncol. 2002 Mar;38(3):178-82. Resumo
126. Braier J, Chantada G, Rosso D, et al. Langerhans cell histiocytosis: retrospective evaluation of 123 patients at a single institution. Pediatr Hematol Oncol. 1999 Sep-Oct;16(5):377-85. Resumo
127. Haupt R, Nanduri V, Calevo MG, et al. Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group. Pediatr Blood Cancer. 2004 May;42(5):438-44. Resumo
128. Egeler RM, Neglia JP, Arico M, et al. The relation of Langerhans cell histiocytosis to acute leukemia, lymphomas, and other solid tumors. The LCH-Malignancy Study Group of the Histiocyte Society. Hematol Oncol Clin North Am. 1998 Apr;12(2):369-78. Resumo
129. ClinicalTrials.gov. LCH-III: treatment protocol of the third international study for Langerhans cell histiocytosis. 2016 [internet publication].Texto completo
O uso deste conteúdo está sujeito ao nosso aviso legal